Breaking: Tyson Foods Q3 Misses Mark; Ginkgo Bioworks' Merck Deal Shakes Up
- August 07th, 2023
- 394 views
Tyson Foods, Inc. (NYSE: TSN) has released its third-quarter fiscal 2023 financial results, reporting adjusted earnings per share (EPS) of $0.15 and revenues totaling $13.14 billion. These figures fell short of market consensus estimates of $0.26 EPS on revenues of $13.59 billion.
$TSN was trading at $52.67 in pre-market, down $3.79 (-6.71%).
In other news, Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) has unveiled a strategic partnership with Merck & Co., Inc. (NYSE: MRK).
The collaboration agreement, which marks the second between the companies and is aimed at improving biologic manufacturing, outlines the potential for Ginkgo to receive up to $490 million, encompassing upfront research fees, milestones, and commercial payments.
In pre-market, $DNA was trading at $2.18, reflecting an increase of $0.14 (+6.86%).
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Key Earnings Ahead for Netflix, Fastenal, and U.S. Bancorp
January 18th, 2026Louisville Thunder Appoints Veteran Coach Mike Reed to Lead Program
January 15th, 2026FDA Approves First Treatment for Children With Menkes Disease
January 13th, 2026January 13th, 2026Wall Street Eyes Bank of America, Wells Fargo, Citi Ahead of Earnings
January 11th, 2026
Member Login